Table 4.

Effect of DHC and concurrent different treatments on HFABP, copeptin, CRP, and MPO.

Parameters	NG	DHC	10-DHGD	VIT.D	10-DHGD+VIT.D
HFABP mRNA	1.01 ± 0.014	7.01 ± 0.142*	2.70 ± 0.377#	4.32 ± 0.215#a	1.84 ± 0.176#ab
Copeptin mRNA	1.04 ± 0.023	8.92 ± 0.147*	3.14 ± 0.137#	5.00 ± 0.142#a	2.02 ± 0.171#ab
CRP (mg/l)	0.37 ± 0.08	3.73 ± 0.67*	0.59 ± 0.05#	0.89 ± 0.10#	0.40 ± 0.03#
MPO (ng/ml)	2.89 ± 0.43	19.04 ± 2.75*	6.60 ± 0.40#	8.88 ± 0.44#a	4.1 ± 0.49#ab

NG: normal groups; DHC: diabetic hyperlipidemic rats received no drugs; 10-DHGD: 10-dehydrogingerdione, VIT.D: vitamin D3, 10-DHGD+VIT.D: combination therapy; HFABP: heart fatty acid binding protein; copeptin; CRP: C-reactive protein, MPO: myeloperoxidase.

^*p < 0.0001: NG vs. DHC; ^#p < 0.0001: DHC vs. treated groups.

^ap <  0.0001; 10-DHGD vs. vit.D3 and combined therapy.

^bp <  0.0001; vit.D3 vs. combined therapy.